Description

McMaster University and MILO are excited to be hosting a Therapeutics Symposium, focused on the next generation of therapeutics being developed to address unmet clinical needs. Distinguished guests from various sectors will cover the following themes:

Partnering and Investment

There is an increasing reliance on academia and start-up companies for scientifically and/or medically innovative drugs. Downstream partners and investors will discuss the opportunities and some of the challenges of commercializing early stage discoveries.

McMaster Therapeutic Start-Ups

We will hear from the scientific founders and/or business leaders of McMaster therapeutic start-up companies including Fusion, Turnstone, Adapsyn, Triumvira and Empirica about the journey from academic discovery to commercial development.

Start-Up Support

Representatives from government and non-profit organizations will discuss how they support start-up companies and how the overall ecosystem for start-up companies can be improved.

Agenda (Presentations and Panels)

9:00am – 12:00 pm

• – Jerel Davis, Managing Director, Versant Ventures
• – Iain Stewart, President, National Research Council Canada (NRC)
• – Damian Lamb, Managing Director, Genesys Capital
• – David O’Neil, President, FACIT
• – Brian Bloom, CEO, Bloom Burton & Co
• – TBA, Ontario Genomics
• – Robert Verhagen, CEO, Centre for Commercialization of Antibodies and Biologics (CCAB)
• – Gail Garland, CEO, Ontario Bioscience Innovation Organization (OBIO)
• – Allan Miranda, Head of JLABS Canada, JLABS, Johnson & Johnson Innovation

1:00pm – 5:00pm

• – John Valliant, CEO, Fusion Pharmaceuticals
• – Brian Lichty, SVP Basic Research, Turnstone Biologics
• – Andy Haigh, COO, Adapsyn Biosciences
• – Sheila Singh, CEO, Empirica Therapeutics
• – Jonathan Bramson, CSO, Triumvira Immunologics

Lunch and refreshments will be served

If you have any questions please contact us: [email protected]